Patents by Inventor Amy E. Schaberg

Amy E. Schaberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130291860
    Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, applying about 0.8-3 mL of a solution comprising about 18-65 mg/mL of denufosol into a medication reservoir of an nebulizer to achieve a target loading dose of denufosol of about 25-52 mg denufosol per dosing regimen, nebulizing the solution by passing through holes of an vibrating mesh device equipped with an oscillating membrane in the nebulizer, and delivering an inhaled respiratory dose of 20-33 mg to the lungs of the patient by inhalation within 3-9 minutes.
    Type: Application
    Filed: October 6, 2011
    Publication date: November 7, 2013
    Inventors: Ramesh Krishnamoorthy, Carole Evans, Brian J. Burke, Amy E. Schaberg, Thomas G. Coady
  • Patent number: 8168597
    Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: May 1, 2012
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Donald J. Kellerman, Ramesh Krishnamoorthy, José L. Boyer, Amy E. Schaberg
  • Publication number: 20100099635
    Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.
    Type: Application
    Filed: October 21, 2009
    Publication date: April 22, 2010
    Inventors: Donald J. Kellerman, Ramesh Krishnamoorthy, José L. Boyer, Amy E. Schaberg